Kuda Therapeutics

Kuda Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics that target the mitochondrial pyruvate carrier (MPC). By modulating the transport of pyruvate into the mitochondria, the company aims to address fundamental metabolic imbalances that drive chronic diseases. Their primary research efforts are directed toward metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and certain oncology indications. Kuda's approach leverages deep expertise in mitochondrial biology to create first-in-class treatments for patients with high unmet medical needs.